Antibody therapies could be a bridge to a coronavirus vaccine — but will the world benefit?

Heidi Ledford

Nature, 2020, vol. 584, issue 7821, 333-334

Abstract: Monoclonal antibodies are complex and expensive to produce, meaning poor countries might be priced out.

Keywords: Policy; SARS-CoV-2; Medical research; Infection (search for similar items in EconPapers)
Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/d41586-020-02360-y Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:584:y:2020:i:7821:d:10.1038_d41586-020-02360-y

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/d41586-020-02360-y

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().